Does TALAZOPARIB Cause Disseminated intravascular coagulation? 5 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Disseminated intravascular coagulation have been filed in association with TALAZOPARIB (Talzenna). This represents 0.3% of all adverse event reports for TALAZOPARIB.
5
Reports of Disseminated intravascular coagulation with TALAZOPARIB
0.3%
of all TALAZOPARIB reports
5
Deaths
1
Hospitalizations
How Dangerous Is Disseminated intravascular coagulation From TALAZOPARIB?
Of the 5 reports, 5 (100.0%) resulted in death, 1 (20.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Disseminated intravascular coagulation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TALAZOPARIB Cause?
Anaemia (219)
Neoplasm progression (169)
Death (142)
Off label use (78)
Thrombocytopenia (78)
Fatigue (77)
Platelet count decreased (68)
Haemoglobin decreased (65)
Febrile neutropenia (60)
Pancytopenia (60)
What Other Drugs Cause Disseminated intravascular coagulation?
PREDNISOLONE (362)
METHOTREXATE (347)
DEXAMETHASONE (323)
METHYLPREDNISOLONE (307)
NIVOLUMAB (305)
CYCLOPHOSPHAMIDE (286)
TACROLIMUS (278)
PREDNISONE (277)
VINCRISTINE (245)
OXALIPLATIN (231)
Which TALAZOPARIB Alternatives Have Lower Disseminated intravascular coagulation Risk?
TALAZOPARIB vs TALC
TALAZOPARIB vs TALIGLUCERASE ALFA
TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC
TALAZOPARIB vs TALQUETAMAB
TALAZOPARIB vs TALQUETAMAB-TGVS